Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 2/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17667847 | 1.00 | ERCC1 (0.51) | ERCC1ERCC4KMT2ATPSAB1PLG | |
| SCHEMBL18887748 | 0.87 | ERCC1 (0.67) | ERCC1ERCC4KMT2ATPSAB1PLG | |
| SCHEMBL11294240 | 0.84 | MEN1 (0.61) | KMT2AMEN1LMNAHPGD | |
| SCHEMBL9200501 | 0.84 | CARM1 (0.56) | ERCC1ERCC4TPSAB1PLGPRSS1 | |
| SCHEMBL9199910 | 0.84 | CARM1 (0.56) | ERCC1ERCC4TPSAB1PLGPRSS1 | |
| SCHEMBL9062437 | 0.83 | KMT2A (0.65) | KMT2AMEN1MAPT | |
| SCHEMBL10405578 | 0.83 | KMT2A (0.65) | KMT2AMEN1MAPT | |
| SCHEMBL5060920 | 0.82 | KDM4E (0.64) | KDM4EF13A1LMNAMAPT | |
| SCHEMBL5411543 | 0.82 | LMNA (0.49) | ERCC1ERCC4KMT2ATPSAB1PLG | |
| SCHEMBL5411548 | 0.82 | LMNA (0.49) | ERCC1ERCC4KMT2ATPSAB1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | ERCC1 3907/4885ERCC4 4486/4885KMT2A 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.